| RA | UPIA | Others | p a | p b | p c |
---|---|---|---|---|---|---|
Number | 32 | 14 | 23 | - | - | - |
Age, mean ± SD (years) | 54.2 ± 17.9 | 47.8 ± 13.1 | 47.8 ± 16.7 | ns | ns | ns |
N. females/males, (% F) | 24/8 (75.0) | 11/3 (78.6) | 14/9 (60.9) | ns | ns | ns |
Duration, mean ± SD (years) | 6.5 ± 7.5 | 3.6 ± 5.3 | 3.8 ± 6.2 | ns | ns | ns |
ESR, mean ± SD (mm 1 st h) | 62.1 ± 39.2 | 33.6 ± 26.8 | 35.9 ± 30.9 | 0.02 | 0.01 | ns |
CRP, mean ± SD (mg/l) | 40.7 ± 47.4 | 15.6 ± 16.9 | 28.6 ± 49.0 | ns | ns | ns |
DAS, mean ± SD | 3.74 ± 1.17 | 2.25 ± 0.85 |  | <0.01 | - | - |
HAQ-DI, mean ± SD | 1.40 ± 0.78 | 0.69 ± 0.91 | 0.91 ± 0.72 | 0.01 | 0.04 | ns |
ACPA ≥5.0 U/ml (%) | 13 (40.6) | 1 (7.7) | 1 (4.5) | <0.01 | <0.01 | ns |
IgM RF ≥20.0 U/ml (%) | 9 (28.1) | 2 (15.4) | 1 (4.5) | ns | 0.05 | ns |
IgA RF ≥20.0 U/ml (%) | 6 (18.8) | 1 (7.7) | 0 | ns | ns | ns |
DMARDs therapy, n. (%) | 27 (84.4) | 8 (57.1) | 19 (82.6) | ns | ns | ns |
Biologic therapy, n. (%) | 10 (31.3) | 0 | 2 (8.7) | 0.02 | 0.05 | ns |
Steroid therapy, n. (%) | 22 (68.8) | 6 (42.9) | 12 (52.2) | ns | ns | ns |